AbbVie (ABBV)
210.40
+0.00 (0.00%)
NYSE · Last Trade: Sep 2nd, 9:23 AM EDT
Over $11 billion flowed into the popular healthcare sector ETF XLV in Q2 alone, suggesting smart money is positioning for a potential rebound.
Via MarketBeat · September 2, 2025
Selling these dividend stocks isn't on my radar at all.
Via The Motley Fool · August 31, 2025
You won't need a lot of money up front to begin raking in dividends from these great stocks.
Via The Motley Fool · August 30, 2025
Deal activity this week included PepsiCo, Sycamore and Bain while the bankruptcy front included SSENSE and Dr. Phil.
Via Benzinga · August 29, 2025
AbbVie Seeks To Expand Psychiatry Pipeline By Acquiring Gilgamesh’s Lead Candidate For Up To $1.2Bstocktwits.com
Via Stocktwits · August 25, 2025
AbbVie’s Investigational Drug For Alopecia Yields Positive Outcomes In Late-Stage Studystocktwits.com
Via Stocktwits · August 21, 2025
AbbVie currently trades at $207.60 per share and has shown little upside over the past six months, posting a small loss of 0.7%. The stock also fell short of the S&P 500’s 9.2% gain during that period.
Via StockStory · August 29, 2025
Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.
Via MarketBeat · August 26, 2025
Via Benzinga · August 26, 2025
These great businesses can help patient investors beat the market.
Via The Motley Fool · August 24, 2025
Investors will get great dividends and more with these stocks.
Via The Motley Fool · August 23, 2025
Daily stock price moves often dominate headlines, but shifts in fundamental ranking scores can reveal a deeper story. This week, Benzinga's proprietary Growth data highlighted major swings among household names.
Via Benzinga · August 22, 2025
Sit back and let the income roll in with this great exchange-traded fund.
Via The Motley Fool · August 22, 2025
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Via StockStory · August 22, 2025
The annual Jackson Hole Economic Policy Symposium, a highly anticipated gathering of global central bankers, finance ministers, and leading economists, is currently underway in Wyoming. This year's symposium is particularly significant as Federal Reserve Chair Jerome Powell's final keynote address before his term concludes in May 2026 is expected to
Via MarketMinute · August 21, 2025
Global financial markets are on tenterhooks, fixated on the highly anticipated speech by Federal Reserve Chair Jerome Powell at the annual Jackson Hole Economic Symposium. Investors are keenly awaiting any signals regarding the future trajectory of U.S. monetary policy, with a significant portion of the market pricing in a
Via MarketMinute · August 21, 2025
Via Benzinga · August 21, 2025
AbbVie's Rinvoq Phase 3 trial showed strong efficacy in severe alopecia areata, with many patients achieving significant scalp hair regrowth by week 24.
Via Benzinga · August 21, 2025
These high-yield dividend stocks are built to last.
Via The Motley Fool · August 21, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.
Via StockStory · August 19, 2025
The financial world is abuzz with anticipation as the annual Jackson Hole Economic Symposium draws near, an exclusive gathering hosted by the Federal Reserve Bank of Kansas City in the serene mountains of Wyoming. This highly influential event, bringing together central bank leaders, economists, and financial market participants from across
Via MarketMinute · August 19, 2025
Investor sentiment is overwhelmingly pointing towards a significant shift in the Federal Reserve's monetary policy, with a near-certainty of a 25-basis-point interest rate cut anticipated at its September meeting. This widespread expectation, currently hovering around a 92% probability, is sending ripples through financial markets, influencing everything from stock valuations to
Via MarketMinute · August 19, 2025
You'd be sitting pretty right now.
Via The Motley Fool · August 18, 2025
Marjorie Taylor Greene may have another winning stock trade with a new filing showing a purchase of UnitedHealth stock.
Via Benzinga · August 15, 2025